| 38.79 -1.26 (-3.15%) | 05-22 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 61.98 | 1-year : | 75.68 |
| Resists | First : | 53.07 | Second : | 64.8 |
| Pivot price | 41.34  |
|||
| Supports | First : | 34.09 | Second : | 28.37 |
| MAs | MA(5) : | 38.63  |
MA(20) : | 46.4 |
| MA(100) : | 85.47 |
MA(250) : | 112.53 |
|
| MACD | MACD : | -6.7 |
Signal : | -7.2 |
| %K %D | K(14,3) : | 17.9 |
D(3) : | 16 |
| RSI | RSI(14): 32.1 |
|||
| 52-week | High : | 173.25 | Low : | 34.09 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ SRPT ] has closed above bottom band by 43.0%. Bollinger Bands are 62% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 11 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 40.12 - 40.33 | 40.33 - 40.45 |
| Low: | 38.21 - 38.48 | 38.48 - 38.65 |
| Close: | 38.41 - 38.81 | 38.81 - 39.07 |
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Thu, 22 May 2025
SRPT: HC Wainwright & Co. Reiterates Neutral Rating on Sarepta Therapeutics | SRPT Stock News - GuruFocus
Wed, 21 May 2025
Sarepta Therapeutics (NasdaqGS:SRPT) Continues Phase 3 Study of ELEVIDYS Gene Therapy in Duchenne - simplywall.st
Wed, 21 May 2025
Sarepta Provides Update on UK Dosing in ENVISION Study of ELEVIDYS for the treatment of Duchenne Muscular Dystrophy - Business Wire
Tue, 20 May 2025
Sarepta Therapeutics (SRPT) Price Target Reduced by JPMorgan | S - GuruFocus
Fri, 09 May 2025
Is Sarepta Therapeutics, Inc. (SRPT) The Best Stock That Will Bounce Back? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 98 (M) |
| Shares Float | 94 (M) |
| Held by Insiders | 4.4 (%) |
| Held by Institutions | 88.1 (%) |
| Shares Short | 6,700 (K) |
| Shares Short P.Month | 6,100 (K) |
| EPS | -2.65 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 11.63 |
| Profit Margin | -11.2 % |
| Operating Margin | -40.4 % |
| Return on Assets (ttm) | -2.2 % |
| Return on Equity (ttm) | -23.7 % |
| Qtrly Rev. Growth | 80.1 % |
| Gross Profit (p.s.) | 4.57 |
| Sales Per Share | 22.69 |
| EBITDA (p.s.) | -0.8 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -547 (M) |
| Levered Free Cash Flow | -741 (M) |
| PE Ratio | -14.7 |
| PEG Ratio | 0 |
| Price to Book value | 3.33 |
| Price to Sales | 1.7 |
| Price to Cash Flow | -6.97 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|